Clinical Trials | January 06, 2026
BioInvent’s experimental combo shows promise in hard-to-treat ovarian cancer
Pembrolizumab has shown meaningful benefit only when combined with chemotherapy
Pembrolizumab has shown meaningful benefit only when combined with chemotherapy
The company said it received notice on January 1 from the FDA’s Center for Veterinary Medicine that the funding will support its ongoing effectiveness study of Canalevia-CA1
He noted the enduring relevance of Siddha medicine as “a comprehensive, preventive and sustainable healthcare system in the contemporary world
Singh previously served as Head of IT (Development and Manufacturing Services) at Syngene International Limited, Lead of IT Manufacturing at UPL, and AGM at The Hi-Tech Gears
The filing clears the regulatory path for potential first-in-human trials and marks a key advance in the company’s chronic inflammatory disease pipeline
Leaders from science, policy, industry, and investment came together in New Delhi to examine how alignment across the biotechnology value chain can turn innovation into outcomes at scale
His professional background also includes key experience at Matrix Labs and Sun Pharma
The portfolio, purchased from a leading multinational generic manufacturer, addresses a market valued at $473.2 million for the 12 months ending August 2025
The company’s consolidated revenue from operations rose to Rs. 361.13 crore in Q2 FY26 and Rs. 707.67 crore for the first half
The company announced that it has been granted patent covering “Substituted Ethylamine Fused Heterocyclic Mescaline Derivatives.”
Subscribe To Our Newsletter & Stay Updated
